Incyte (INCY) Tops Q4 EPS by 20c
Get Alerts INCY Hot Sheet
Price: $52.35 -0.89%
Revenue Growth %: +14.9%
Financial Fact:
Diluted (in dollars per share): 0.19
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +14.9%
Financial Fact:
Diluted (in dollars per share): 0.19
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q4 EPS of $0.29, $0.20 better than the analyst estimate of $0.09. Revenue for the quarter came in at $243.9 million versus the consensus estimate of $225.92 million.
2016 guidance for Jakafi net product revenues in the range of $800 million to $815 million, reflecting expectations for continued growth in underlying demand in myelofibrosis (MF) and an increasing contribution from the ongoing launch in polycythemia vera (PV)
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Wipro (WIT) Tops Q1 EPS by 1c
- Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!